Open Access

Role of adhesion molecules and inflammation in Venezuelan equine encephalitis virus infected mouse brain

  • Anuj Sharma1,
  • Manish Bhomia1, 2,
  • Shelley P Honnold1 and
  • Radha K Maheshwari1Email author
Virology Journal20118:197

https://doi.org/10.1186/1743-422X-8-197

Received: 7 February 2011

Accepted: 29 April 2011

Published: 29 April 2011

Abstract

Background

Neuroinvasion of Venezuelan equine encephalitis virus (VEEV) and subsequent initiation of inflammation in the brain plays a crucial role in the outcome of VEEV infection in mice. Adhesion molecules expressed on microvascular endothelial cells in the brain have been implicated in the modulation of the blood brain barrier (BBB) and inflammation in brain but their role in VEEV pathogenesis is not very well understood. In this study, we evaluated the expression of extracellular matrix and adhesion molecules genes in the brain of VEEV infected mice.

Findings

Several cell to cell adhesion molecules and extracellular matrix protein genes such as ICAM-1, VCAM-1, CD44, Cadherins, integrins, MMPs and Timp1 were differentially regulated post-VEEV infection. ICAM-1 knock-out (IKO) mice infected with VEEV had markedly reduced inflammation in the brain and demonstrated a delay in the onset of clinical symptoms of disease. A differential regulation of inflammatory genes was observed in the IKO mice brain compared to their WT counterparts.

Conclusions

These results improve our present understanding of VEEV induced inflammation in mouse brain.

Findings

Neurovirulent Venezuelan equine encephalitis virus (VEEV) is a member of the genus Alphavirus, in the family Togaviridae. VEEV causes lethal encephalitis in equines and occasionally infect humans [1, 2]. In our earlier studies, we have reported upregulation of several integrins (Itg) and integrin binding molecule genes such as nischarin (Nisch) and integrin alpha V (ItgaV) as well as genes that are implicated in the alteration of the blood brain barrier (BBB) such as MCP-1 [3] in the brains of VEEV infected mice [4, 5]. Other studies have also shown that adhesion molecules expressed on the surface of microvascular endothelial cells of the BBB play an important role in viral encephalitis [6, 7]. VEEV replicon particles have also been recently reported to disrupt BBB [8]. Though, VEEV has been known to enter the central nervous system (CNS) through the olfactory tract, these studies indicate that adhesion molecules expressed on the BBB may also play role in VEEV pathogenesis [2]. Therefore, in this study, we evaluated the expression of extracellular matrix (ECM) and adhesion molecules in VEEV infected CD-1 mice brain. Several ECM and adhesion molecules genes, such as integrins (ItgαX, Itg2, 3, and 7), cadherin (Cdh) 1 and 2, intracellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule (VCAM-1) were found to be upregulated in the brains of VEEV infected CD-1 mice (Table 1). Immunohistochemistry analysis showed ICAM-1 expression and its co-localization with inflammation, fibrinogen leakage and VEEV antigen in and around the brain microvessels (Figure 1). Pathway analysis of the modulated ECM and adhesion molecules genes using DAVID software [9, 10] indicated their involvement in leukocyte migration at BBB (Additional file 1 Figure S1). Of these several genes, ICAM-1 has been implicated in the pathogenesis of various other neurotropic viruses such as West Nile virus, Semliki Forest virus, Theiler's murine encephalomyelitis virus and lymphocyte choriomeningitis virus [1114]. To test if ICAM-1 plays any role in VEEV pathogenesis, ICAM-1 knockout (IKO) mice (B6.129S4-Icam1tm1Jcgr/J, stock No. 002867, Jackson Laboratories, Bar Harbor, Maine, USA) were infected with 1000 pfu of VEEV in two separate studies. In both these studies, VEEV infected wild type (WT; C57BL/6J, stock No. 000664, Jackson Laboratories, Bar Harbor, Maine, USA) mice became sick earlier than the ICAM-1 knock-out (IKO) mice. IKO mice showed delayed appearance of the clinical symptoms such as shivering, excitability, and hind limb paralysis with a total loss of mobility. General health and appearance of the WT mice evaluated as ruffled fur, hunched back posture and lethargy in the early stages of the disease was severe than similarly infected IKO mice. IKO mice were more responsive to touch, less lethargic and were eating better than the WT mice. Though a 20% reduction in mortality was observed in both the studies (Figure 2), there was no difference in the mean survival time of the IKO mice that succumbed to VEEV infection as compared to the WT mice. Histopathological analysis of brain showed less severe single cell necrosis and perivascular cuffing in the IKO mice brain than the WT mice at 96 hr post infection (pi) (Figure 3). However, no significant difference in VEEV antigen was noticed (data not shown) in the brains of IKO and WT mice. The inflammatory cytokine specific focused microarray performed on the brain RNA samples of VEEV infected WT and IKO mice at 96 hr pi (Table 2) showed inflammatory gene expression differences in the brain of IKO mice. Basal level differences in the cytokine expression of uninfected IKO and WT brain are given in additional file 2 Table S1. Microarray analysis (Table 2) showed a complex inflammatory response to VEEV infection in the brain of IKO mice which can be classified based on pro- and anti-inflammatory response and may explain some of the differences seen early in the infection of IKO and WT mice. Several pro-inflammatory cytokines/ligands such as Ccl24, Cxcl11 and Cxcl13 were down regulated in IKO mice brain as compared to WT mice. Ccr2, a chemokine receptor that is involved in the migration of peripheral blood mononuclear cells into the brain [15] was also down regulated in the brains of VEEV infected IKO mice. Anti-inflammatory genes IL10, Ccl22 and IL22 were also down regulated in the brains of VEEV infected IKO mice. These cytokines and chemokines have been implicated in the regulation and suppression of inflammation in the tissues [1619]. Other pro-inflammatory genes such as Ccr1 and Xcl1 that have been implicated in the recruitment of mononuclear phagocytes and T cells respectively into the brain [2023] were either upregulated or induced in the VEEV infected IKO mice brain. Modulation of these anti-inflammatory and pro-inflammatory genes may contribute to the final outcome of inflammation observed in the brain of VEEV infected IKO mice. Gene expression evaluation at early and later time points than 96 hr pi may shed more light on the inflammatory gene expression kinetics in the brain of IKO mice. To further evaluate if inflammation is crucial, animals were treated with a known anti-inflammatory drug naproxen (40 mg/kg, once a day). Similar to the VEEV infected IKO mice, naproxen treated VEEV infected CD-1 mice (n = 10) early in the infection (0-5 days) showed lesser degree of ruffled fur, lethargy, hunched back, and delayed appearance of shivering and paralysis as compared to the untreated mice (n = 10), thereafter, these mice quickly became sick and there was no difference in the mean survival time of naproxen treated and untreated VEEV infected mice. A marked decrease but not total ablation in the vascular inflammation was observed in the naproxen treated VEEV-infected mice at 96 and 120 hr pi (n = 3 each group) (Figure 4). Viral load in the brain was evaluated by RT-PCR at 48, 72, 96 and 120 hr pi (n = 5 each group). There was no significant difference in the viral load in the brain of the naproxen treated and untreated VEEV infected mice groups. However, when taken as individual sets of mice, more viral load was observed in the brain of some of the naproxen treated mice as compared to the untreated ones (Figure 5). Treatment with ribavirin (80 mg/kg, once a day), a known anti-viral drug, alone or in combination with naproxen also did not affect the mortality or the viral load in VEEV infected mice. These results show a complex role of inflammation in VEEV pathology, initial better health of naproxen treated mice may be due to reduced inflammation in the brain. However, increase in brain viral load in naproxen treated animals may be due to unchecked viral replication due to reduced inflammation.
Table 1

Mouse extracellular matrix and adhesion molecules gene(s) differentially expressed by two fold in VEEV infected CD 1 mouse brain.

Position on Array

Ref Sequence Number

Functional Grouping (Gene)

Fold expression over uninfected controls

   

48 hr pi

72 hr pi

96 hr pi

120 hr pi

Cell Adhesion molecules: Transmembrane/cell-cell adhesion/cell-matrix adhesion/other molecules

9

NM_009851

CD44 antigen (Cd44)

(A)

5.24 (PI) ± 4.24 (0.37)

16.35 (PI) ± 10.09 (0.20)

34.83 (PI) ± 3.23 (0.0004)

10

NM_009864

Cadherin 1 (Cdh1)

3.97 ± 0.32 (0.0007)

4.98 ± 3.37 (0.30)

6.52 ± 5.23 (0.35)

16.79 ± 1.57 (0.0005)

14

NM_009868

Cadherin 5 (Cdh5)

(A)

1.17 (PI) ± 0.17 (0.37)

1.92 (PI) ± 0.59(0.19)

9.57 (PI) ± 0.97 (0.0009)

29

NM_016919

Procollagen, type V, alpha 3 (Col5a3)

0.81 ± 0.15 (0.51)

1.09 ± 0.19 (0.78)

1.60 ± 0.67 (0.16)

2.07 ± 0.31 (0.03)

32

NM_007739

Procollagen, type VIII, alpha 1 (Col8a1)

1.41 ± 0.49 (0.53)

1.77 ± 1.31(0.27)

1.18 ± 0.39 (0.70)

0.80 ± 0.61 (0.65)

34

XM_488510/

NM_001081249.1

Mus musculus chondroitin sulfate proteoglycan 2(Cspg2)/Versican (Vcan)

1.14 ± 0.40 (0.74)

2.36 ± 0.80 (0.28)

3.34 ± 1.13 (0.23)

4.39 ± 1.83 (0.07)

35

NM_010217

Connective tissue growth factor (Ctgf)

0.88 ± 0.13 (0.38)

0.91 ± 0.13 (0.52)

0.83 ± 0.05 (0.24)

0.45 ± 0.10 (0.01)

38

NM_009848

Ectonucleoside triphosphate diphosphohydrolase 1(Entpd1)

(A)

(A)

(A)

4.37 (PI) ± 1.41 (0.03)

41

NM_013500

Hyaluronan and proteoglycan link protein 1 (Hapln1)

0.67 (PI) ± 0.29

1.15 (PI) ± 0.13 (0.73)

(A)

(A)

43

NM_010493

Intercellular adhesion molecule (Icam1)

2.82 (PI) ± 1.32 (0.24)

8.4 (PI) ± 3.00 (0.07)

13.51 (PI) ± 6.24 (0.12)

36.76 (PI) ± 4.81 (0.001)

56

NM_021334

Integrin alpha × (Itgax)

(A)

(A)

4.49 ± 1.12 (0.01)

3.55 (PI) ± 0.89 (0.02)

57

NM_010578

Integrin beta 1 (fibronectin receptor beta) (Itgb1)

1.06 ± 0.48 (0.83)

1.61 ± 0.35 (0.27)

2.41 ± 0.56 (0.02)

2.67 ± 0.39 (0.01)

58

NM_008404

Integrin beta 2 (Itgb2)

(A)

(A)

(A)

4.79 (PI) ± 0.27 (0.0.0001)

59

NM_016780

Integrin beta 3 (Itgb3)

1.36 (PI) ± 0.25 (0.59)

2.32 (PI) ± 0.30 (0.10)

3.37 (PI) ± 1.32 (0.03)

3.06 (PI) ± 0.55 (0.01)

63

NM_013566

Integrin beta 7 (Itgb7)

0.83 ± 0.13 (0.50)

(A)

3.40 ± 1.98 (0.27)

7.84 (PI) ± 3.04 (0.04)

96

NM_011346

Selectin, lymphocyte (Sell)

2.67 (PI) ± 0.89 (0.33)

10.06 (PI) ± 5.41 (0.08)

20.37(PI) ± 11.02 (0.07)

21.45 (PI) ± 5.60 (0.001)

97

NM_011347

Selectin, platelet (Selp)

12.66 (PI) ± 8.84 (0.26)

32.57 (PI) ± 2.66 (0.0002)

43.14 (PI) ± 5.70 (0.001)

37.60 (PI) ± 4.37 (0.001)

105

NM_011581

Thrombospondin 2 (Thbs2)

1.17 ± 0.34 (0.58)

1.60 ± 0.82 (0.44)

2.87 ± 1.58 (0.40)

4.02 ± 3.50 (0.39)

107

NM_011582

Thrombospondin 4 (Thbs4)

11.99 ± 3.25 (0.03)

2.70 ± 1.19 (0.22)

1.30 ± 0.30 (0.37)

(A)

Extracellular Matrix Proteins: Basement membrane constituents/ECM proteases and their inhibitors/others

5

NM_013906

A disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 8 (Adamts8)

(A)

2.44 (PI) ± 0.34 (0.01)

(A)

2.78 (PI) ± 0.41 (0.01)

16

NM_007729

Procollagen, type XI, alpha 1 (Col11a1)

(A)

2.60 ± 1.61(0.37)

(A)

(A)

77

NM_008608

Matrix metallopeptidase 14 (membrane-inserted) (Mmp14)

0.51 ± 0.09 (0.05)

1.07 ± 0.12 (0.76)

1.32 ± 0.28 (0.11)

1.24 ± 0.20 (0.17)

78

NM_008609

Matrix metallopeptidase 15 (Mmp15)

(A)

(A)

2.48 ± 1.48 (0.37)

(A)

79

NM_019724

Matrix metallopeptidase 16 (Mmp16)

0.49 ± 0.16 (0.09)

1.62 ± 0.07 (0.22)

0.68 ± 0.26 (.035)

1.18 ± 0.32 (0.65)

87

NM_010809

Matrix metallopeptidase 3 (Mmp3)

4.60 (PI) ± 3.34 (0.34)

29.25 (PI) ± 8.41 (0.03)

48.06 (PI) ± 2.98 (0.00009)

26.60 (PI) ± 5.76 (0.01)

89

NM_008611

Matrix metallopeptidase 8 (Mmp8)

1.21 ± 0.29 (0.46)

(A)

6.15 ± 4.73 (0.38)

22.59 (PI) ± 6.94 (0.05)

101

NM_009263

Secreted phosphoprotein 1 (Spp1)

1.00 ± 0.03 (0.99)

0.67 ± 0.18 (0.12)

0.63 ± 0.17 (0.12)

0.50 ± 0.06 (0.01)

103

NM_009369

Transforming growth factor, beta induced (Tgfbi)

0.87 ± 0.10 (0.40)

0.55 ± 0.19 (0.15)

0.06 ± 0.04 (0.001)

0.08 ± 0.06 (0.001)

108

NM_011593

Tissue inhibitor of metalloproteinase 1 (Timp1)

(A)

4.88 (PI) ± 2.38 (0.18)

17.64 (PI) ± 5.88 (0.05)

13.79 (PI) ± 1.36 (0.0007)

112

NM_011607

Tenascin C (Tnc)

(A)

(A)

0.49 ± 0.25 (0.37)

(A)

Genes that are differentially expressed by ≥2.0 fold are represented. Values are represented at mean fold difference ± SEM (P-value). (A) = absent; PI = present in infection and; PC = present in saline control.

Figure 1

ICAM-1 expression corresponds with perivascular cuffing, fibrinogen leakage, and the presence of VEEV in the brains of VEEV infected mice. (a) H&E staining of the brain of VEEV infected CD-1 mice exhibited prominent perivascular cuffs throughout the brain. (b) Endothelial cells are hypertrophied and exhibit positive immunoreactivity for ICAM-1. (c) Immunohistochemistry for fibrinogen demonstrated localized fibrinogen leakage around hypertrophied endothelial cells, indicating disruption of the BBB. (d) Extensive VEEV specific staining revealed numerous cells infected with VEEV around the affected vessels. (e) Perivascular cuffs were composed of moderate numbers of mononuclear cells, primarily lymphocytes and fewer monocytes which had transmigrated the endothelium and multifocally extended into the neuropil. (f) Neurons were primarily infected with VEEV; however, VEEV antigen was also localized in glia and fewer lymphocytes. (g) Vacuolation of the neuropil was observed around the affected vessels.

Figure 2

Survival study in IKO mice. Representative of two separate survival studies done in IKO mice upon VEEV infection is shown here. Mice were observed twice a day for fourteen days pi for signs of clinical disease. There was a 20% reduction in mortality in IKO mice over their WT controls in both the studies.

Figure 3

Inflammation in the brain of VEEV infected IKO and WT mice. (a) IKO 96 hr pi cerebrum, subventricular zone, H&E, 400X: There were low numbers of necrotic neurons, characterized by small amounts of karyorrhexis (arrows), when compared to the same region of the WT mice (b). (b) WT 96n hr pi, cerebrum, subventricular zone, H&E, 400X: There were high numbers of necrotic neurons, characterized by large amounts of karyorrhexis (arrows), when compared to the same region of IKO mice (a). (c) IKO 96 hr pi, brainstem, H&E, 400X: There was little to no endothelial swelling and no perivascular cuffing (arrows) compared to the WT mice (d). (d) WT 96 hr pi, brainstem, H&E, 400X: There was moderate endothelial swelling and mild perivascular cuffing (thick arrows) and rare necrotic cells (thin arrow) compared to the IKO mice (c). (e) IKO 96 hr pi, brain, thalamus, H&E, 400X: There was little to no endothelial swelling and no perivascular cuffing (arrows) compared to the WT mice (f). (f) WT 96 hr pi, brain, thalamus, H&E, 400X: There was moderate endothelial swelling and mild perivascular cuffing (thick arrow) and rare necrotic cells (thin arrows) compared to the IKO mice (e).

Table 2

Differential gene expression in brains of VEEV infected ICAM-1 WT mice (n = 3) as compared to IKO mice (n = 3) at 96 hr pi.

Position

RefSeq Number

Symbol

Description

IKO Mean±SEM

WT

Mean±SEM

Fold Change

(IKO/WT)

7

NM_011332

Ccl17

Chemokine (C-C motif) ligand 17 (Ccl17)

73.57

(A)

P-IKO

13

NM_019577

Ccl24

Chemokine (C-C motif) ligand 24 (Ccl24)

(A)

273.69 POR

P-WT

22

NM_009912

Ccr1

Chemokine (C-C motif) receptor 1 (Ccr1)

132.24 ± (40.75)

28.80 POR

4.59

35

NM_019494

Cxcl11

Chemokine (C-X-C motif) ligand 11 (Cxcl11)

435.04 ± (167.36)

690.98 ± (322.64)

0.63

37

NM_018866

Cxcl13

Chemokine (C-X-C motif) ligand 13 (Cxcl13)

163.29 POR

245.09 ± (156.61) PTwR

0.67

49

NM_008337

Ifng

Interferon gamma (Ifng)

211.35 ± (21.67) PTwR

122.81 ± (12.68) PTwR

1.72

51

NM_010548

Il10

Interleukin 10 (Il10)

(A)

57.40 ± (43.51) PTwR

P-WT

68

NM_008362

Il1r1

Interleukin 1 receptor, type I (Il1r1)

119.93 POR

(A)

P-IKO

69

NM_010555

Il1r2

Interleukin 1 receptor, type II (Il1r2)

287.27 POR

172.19 ± (94.76) PTwR

1.67

73

NM_016971

Il22

Interleukin 22 (Il22)

(A)

186.84 POR

P-WT

74

NM_008368

Il2rb

Interleukin 2 receptor, beta chain (Il2rb)

151.12 POR

31.83 POR

4.75

93

NM_011101

Prkca

Protein kinase C, alpha (Prkca)

60.8 POR

(A)

P-IKO

94

NM_009007

Rac1

RAS-related C3 botulinum substrate 1 (Rac1)

195.79 ± (6.81) PTwR

105.57 ± (81.61) PTwR

1.85

95

NM_007926

Scye1

Small inducible cytokine subfamily E, member 1 (Scye1)

385.53 ± (137.18)

243.61 ± (159.47)

1.58

96

NM_009263

Spp1

Secreted phosphoprotein 1 (Spp1)

693.01 ± (74.26)

389.60 ± (127.58)

1.78

104

NM_133211

Tlr7

Toll-like receptor 7 (Tlr7)

176.40 ± (87.47) PTwR

35.74 ± (22.32) PTwR

4.94

107

NM_013693

Tnf

Tumor necrosis factor (Tnf)

74.90 ± (8.85) PTwR

193.78 POR

0.39

112

NM_008510

Xcl1

Chemokine (C motif) ligand 1 (Xcl1)

76.09 ± (42.81) PTwR

(A)

P-IKO

Average expression values of gene are given. Where gene expression was detected in only one biological sample and not the replicates, the gene expression value is followed by POR (p resent in o ne r eplicate), similarly where the gene expression was detected in two biological replicates the gene expression value is followed by PTwR (p resent in tw o r eplicates). The fold expression values are derived by dividing average expression (or expression value from one or two replicates) of VEEV infected IKO samples with average expression (or expression value from one replicate) of VEEV infected ICAM WT samples and vice versa. PI = Expressed only in VEEV infected samples, PC = Expressed in uninfected saline control samples only, (A) = absent. Values are expressed as ± SEM.

Figure 4

Inflammation was reduced in VEEV infected mice treated with naproxen or naproxen plus ribavirin. Animals were treated with naproxen (40 mg/kg/once a day) only or naproxen plus ribavirin (80 mg/kg/once a day) at the time of infection (1000 pfu of VEEV inoculated in left rear foot pad). Animals were monitored twice a day and clinical symptoms of disease were monitored for two weeks.

Figure 5

Viral load in the brain of mice treated with naproxen and naproxen plus rivavirin. Animals were treated with naproxen and naproxen plus ribavirin as described in the text. Mice were sacrificed at each given time points (n = 5 each group) and brain tissues were evaluated for viral load by RT-PCR. Given is a representative picture of one of the set of the mice. (1) drug treated 120 hr pi; (2) untreated 120 hr pi; (3) drug treated 96 hr pi; (4) untreated 96 hr pi; (5) drug treated 72 hr pi; (6) untreated 72 hr pi; (7) drug treated 48 hr pi; and (8) untreated 48 hr pi.

To our knowledge, this is the first study to evaluate the expression of ECM and adhesion molecules in brain during VEEV infection and to evaluate the inflammatory response in IKO mice during VEEV infection. The results show that adhesion molecules such as ICAM-1 may play an important role in VEEV disease pathology. These findings improve our present understanding of VEEV induced inflammation in the mouse brain and its implication in VEEV disease.

Declarations

Acknowledgements

This work was supported by a grant from Defense Threat Reduction Agency Project ID: 4.10019_07_US_B. The opinions or assertions contained herein are the scientific views of the authors and should not be construed as official or necessarily reflecting the views of the Uniformed Services University of the Health Sciences or the Department of Defense, USA.

Authors’ Affiliations

(1)
Dept of Pathology, Uniformed Services University of the Health Sciences
(2)
Biological Sciences Group, Birla Institute of Technology and Science

References

  1. Charles PC, Trgovcich J, Davis NL, Johnston RE: Immunopathogenesis and immune modulation of Venezuelan equine encephalitis virus-induced disease in the mouse. Virology 2001,284(2):190-202. 10.1006/viro.2001.0878View ArticlePubMedGoogle Scholar
  2. Ryzhikov AB, Ryabchikova EI, Sergeev AN, Tkacheva NV: Spread of Venezuelan equine encephalitis virus in mice olfactory tract. Arch Virol 1995,140(12):2243-2254. 10.1007/BF01323243View ArticlePubMedGoogle Scholar
  3. Eugenin EA, Berman JW: Chemokine-dependent mechanisms of leukocyte trafficking across a model of the blood-brain barrier. Methods 2003,29(4):351-361. 10.1016/S1046-2023(02)00359-6View ArticlePubMedGoogle Scholar
  4. Sharma A, Bhattacharya B, Puri RK, Maheshwari RK: Venezuelan equine encephalitis virus infection causes modulation of inflammatory and immune response genes in mouse brain. BMC Genomics 2008, 9: 289. 10.1186/1471-2164-9-289PubMed CentralView ArticlePubMedGoogle Scholar
  5. Sharma A, Maheshwari RK: Oligonucleotide Array Analysis of Toll Like Receptors and Associated Signaling Genes in Venezuelan Equine Encephalitis Virus Infected Mouse Brain. J Gen Virol 2009,90(Pt 8):1836-47.View ArticlePubMedGoogle Scholar
  6. Dallasta LM, Wang G, Bodnar RJ, Draviam R, Wiley CA, Achim CL, Hamilton RL: Differential expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in chronic murine retroviral encephalitis. Neuropathol Appl Neurobiol 2000,26(4):332-341. 10.1046/j.1365-2990.2000.00249.xView ArticlePubMedGoogle Scholar
  7. Mueller KL, Daniels MA, Felthauser A, Kao C, Jameson SC, Shimizu Y: Cutting edge: LFA-1 integrin-dependent T cell adhesion is regulated by both ag specificity and sensitivity. J Immunol 2004,173(4):2222-2226.View ArticlePubMedGoogle Scholar
  8. Schafer A, Whitmore AC, Konopka JL, Johnston RE: Replicon particles of Venezuelan equine encephalitis virus as a reductionist murine model for encephalitis. J Virol 2009,83(9):4275-4286. 10.1128/JVI.02383-08PubMed CentralView ArticlePubMedGoogle Scholar
  9. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA: DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003,4(5):P3. 10.1186/gb-2003-4-5-p3View ArticlePubMedGoogle Scholar
  10. Huang da W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009,4(1):44-57.View ArticlePubMedGoogle Scholar
  11. Dai J, Wang P, Bai F, Town T, Fikrig E: Icam-1 participates in the entry of west nile virus into the central nervous system. J Virol 2008,82(8):4164-4168. 10.1128/JVI.02621-07PubMed CentralView ArticlePubMedGoogle Scholar
  12. Soilu-Hanninen M, Roytta M, Salmi AA, Salonen R: Semliki Forest virus infection leads to increased expression of adhesion molecules on splenic T-cells and on brain vascular endothelium. J Neurovirol 1997,3(5):350-360. 10.3109/13550289709030749View ArticlePubMedGoogle Scholar
  13. Drescher KM, Zoecklein LJ, Rodriguez M: ICAM-1 is crucial for protection from TMEV-induced neuronal damage but not demyelination. J Neurovirol 2002,8(5):452-458. 10.1080/13550280260422767View ArticlePubMedGoogle Scholar
  14. Christensen JP, Marker O, Thomsen AR: T-cell-mediated immunity to lymphocytic choriomeningitis virus in beta2-integrin (CD18)- and ICAM-1 (CD54)-deficient mice. J Virol 1996,70(12):8997-9002.PubMed CentralPubMedGoogle Scholar
  15. Kyrkanides S, Miller AW, Miller JN, Tallents RH, Brouxhon SM, Olschowka ME, O'Banion MK, Olschowka JA: Peripheral blood mononuclear cell infiltration and neuroinflammation in the HexB-/- mouse model of neurodegeneration. J Neuroimmunol 2008,203(1):50-57. 10.1016/j.jneuroim.2008.06.024PubMed CentralView ArticlePubMedGoogle Scholar
  16. Genovese T, Esposito E, Mazzon E, Di Paola R, Caminiti R, Bramanti P, Cappelani A, Cuzzocrea S: Absence of endogenous interleukin-10 enhances secondary inflammatory process after spinal cord compression injury in mice. J Neurochem 2009,108(6):1360-1372. 10.1111/j.1471-4159.2009.05899.xView ArticlePubMedGoogle Scholar
  17. Marques CP, Hu S, Sheng W, Cheeran MC, Cox D, Lokensgard JR: Interleukin-10 attenuates production of HSV-induced inflammatory mediators by human microglia. Glia 2004,47(4):358-366. 10.1002/glia.20045View ArticlePubMedGoogle Scholar
  18. Wahl C, Wegenka UM, Leithauser F, Schirmbeck R, Reimann J: IL-22-dependent attenuation of T cell-dependent (ConA) hepatitis in herpes virus entry mediator deficiency. J Immunol 2009,182(8):4521-4528. 10.4049/jimmunol.0802810View ArticlePubMedGoogle Scholar
  19. Wilson EH, Wille-Reece U, Dzierszinski F, Hunter CA: A critical role for IL-10 in limiting inflammation during toxoplasmic encephalitis. J Neuroimmunol 2005,165(1-2):63-74. 10.1016/j.jneuroim.2005.04.018View ArticlePubMedGoogle Scholar
  20. Eltayeb S, Berg AL, Lassmann H, Wallstrom E, Nilsson M, Olsson T, Ericsson-Dahlstrand A, Sunnemark D: Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE. J Neuroinflammation 2007, 4: 14. 10.1186/1742-2094-4-14PubMed CentralView ArticlePubMedGoogle Scholar
  21. Franciotta D, Zardini E, Ravaglia S, Piccolo G, Andreoni L, Bergamaschi R, Romani A, Tavazzi E, Naldi P, Ceroni M, et al.: Cytokines and chemokines in cerebrospinal fluid and serum of adult patients with acute disseminated encephalomyelitis. J Neurol Sci 2006,247(2):202-207. 10.1016/j.jns.2006.05.049View ArticlePubMedGoogle Scholar
  22. Kim BO, Liu Y, Zhou BY, He JJ: Induction of C chemokine XCL1 (lymphotactin/single C motif-1 alpha/activation-induced, T cell-derived and chemokine-related cytokine) expression by HIV-1 Tat protein. J Immunol 2004,172(3):1888-1895.View ArticlePubMedGoogle Scholar
  23. Trebst C, Staugaitis SM, Tucky B, Wei T, Suzuki K, Aldape KD, Pardo CA, Troncoso J, Lassmann H, Ransohoff RM: Chemokine receptors on infiltrating leucocytes in inflammatory pathologies of the central nervous system (CNS). Neuropathol Appl Neurobiol 2003,29(6):584-595. 10.1046/j.0305-1846.2003.00507.xView ArticlePubMedGoogle Scholar

Copyright

© Sharma et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement